Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

NEXT STORY
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
PREV STORY
Worldwide Clinical Trials and Science 37® Partner to Advance Agile Clinical Trials™ and Accelerate Study Timelines
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Initial Data from Profound Medical’s TACT Pivotal Clinical Trial Presented at AUA 2018

TORONTO, May 21, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or ...

author_avatar
NASDAQ Market News

Cesca Therapeutics to Announce Fiscal Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on September 19, 2017

RANCHO CORDOVA, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...

author_avatar
NASDAQ Market News

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

author_avatar
NASDAQ Market News